HIV pre-exposure prophylaxis

descriptionPublicationkeyboard_double_arrow_right Article 05 Aug 2014 English Publisher:CMA Joule Inc.Journal:Canadian Medical Association Journal, volume 186, pages E588-E588 (issn: 0820-3946, eissn: 1488-2329,

Copyright policy )

Authors: Malika, Sharma; Darrell H S, Tan;

doi: 10.1503/cmaj.140127

pmid: 25096663

pmc: PMC4203625

HIV pre-exposure prophylaxis

- Summary
- Subjects
- Metrics

Abstract

Currently, PrEP refers to prophylactic daily oral use of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), a formulation that is indicated in Canada for the treatment of HIV infection. Although licensed only in the United States for PrEP, this formulation is used off label in Canada for

Related Organizations

Keywords

Male, Anti-HIV Agents, Risk Factors, Drug Resistance, Viral, Administration, Oral, Humans, Female, HIV Infections, Sexually Transmitted Diseases, Viral

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average